Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Téné M. Yaméogo"'
Autor:
Patrick L.F. Zuber, Bartholomew Dicky Akanmori, Samba O. Sow, Téné M. Yaméogo, Modibo Keita, Mamoudou Harouna Djingarey, Simonetta Viviani, Nehemie Mbakuliyemo, Kirsten S. Vannice, Fabien Diomandé, Marie-Pierre Preziosi, Claude-Roger Ouandaogo
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
A group A meningococcal conjugate vaccine, PsA-TT, was developed by the Meningitis Vaccine Project and the Serum Institute of India, Ltd (SIIL). Clinical trials conducted among approximately 10 000 persons aged 1–29 years, in India and in Africa, c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39de76e27090cc449d824514e23aedc4
http://europepmc.org/articles/PMC4639501
http://europepmc.org/articles/PMC4639501
Autor:
Charles Sawadogo, Fabien V.K. Diomandé, Claude-Roger Ouandaogo, Patrick L.F. Zuber, Rasmata Ouédraogo-Traoré, Nehemie Mbakuliyemo, Lorenzo Pezzoli, Téné M. Yaméogo, Mamoudou Harouna Djingarey, Bassirou Ouedraogo
Publikováno v:
Vaccine. 30:B46-B51
MenAfriVac™ is a new meningococcal A conjugate vaccine developed to prevent meningitis outbreaks in Africa. It was first introduced during the last quarter of 2010 in three West African countries. We report on the monitoring of adverse events follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96cf68bcaa86a8afeb1bda76392f1f36
https://doi.org/10.1016/j.vaccine.2011.12.112
https://doi.org/10.1016/j.vaccine.2011.12.112
Autor:
Patrick L.F. Zuber, Samba O. Sow, Téné M. Yaméogo, Lawrence H. Moulton, Uma Onwuchekwa, Modibo Keita, Anna P. Durbin, Massambou Sacko, Neal A. Halsey, Kirsten S. Vannice, Saad B. Omer, Fabien Diomandé
Publikováno v:
Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
New vaccines, such as those against malaria and dengue, are being developed for use primarily in low-resource countries. Emerging manufacturers provide an increasingly large volume of vaccine products to global programs that will never reach industri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::377a5ff4e64010c8a90879e217db837d
https://pubmed.ncbi.nlm.nih.gov/26553680
https://pubmed.ncbi.nlm.nih.gov/26553680
Autor:
Mamoudou Harouna Djingarey, Patrick L.F. Zuber, Sung Hye Kim, Harouna Bako, Maman S. Chaibou, Téné M. Yaméogo, Mariama Sambo, Laouali Salisou, Lorenzo Pezzoli, William Perea
Publikováno v:
Vaccine. 30(35)
Introduction MenAfriVac is a new conjugate vaccine against Neisseria meningitidis serogroup A, the major cause of meningitis outbreaks in sub-Saharan Africa. In Niger, the MenAfriVac introduction campaign was conducted in the District of Filingue, du
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8492e979f969e830bd888d072dea67dc
https://pubmed.ncbi.nlm.nih.gov/22709955
https://pubmed.ncbi.nlm.nih.gov/22709955